Copyright ©2008 The WJG Press and Baishideng.
World J Gastroenterol. Jun 28, 2008; 14(24): 3773-3780
Published online Jun 28, 2008. doi: 10.3748/wjg.14.3773
Table 1 Ongoing important phase III clinical trials, including monoclonal antibodies and signal transduction/tyrosine kinase inhibitors
TOGAXP or FP +/- trastuzumabAdvanced gastric cancer HER2-positive
AVAGASTXP +/- bevacizumabMetastatic gastric cancer
REAL-3EOX +/- panitumumabAdvanced esophagogastric cancer
FFCD 03-07ECX followed by FOLFIRI vs FOLFIRI followed by ECXAdvanced esophagogastric cancer
EXPANDXP +/- CetuximabAdvanced/Metastatic gastric cancer
MAGIC-BPerioperative ECX +/- bevacizumabNeo-adjuvant gastric cancer
CLASSICXELOX vs observationAdjuvant gastric cancer